Evolving Considerations in the Treatment and Management of Chronic Lymphocytic Leukemia (CLL)

A continuing medical education activity provided by NAMCP and AAMCN

This activity is an archive of the live session from the 2021 Spring Managed Care Forum. If you participated in the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from July 1, 2021 – August 1, 2022

Instructions for CME/NCPD: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.


Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This activity is supported by educational grants from
AbbVie, Adaptive Biotechnologies, AstraZeneca, Beigene, and Pharmacyclics

Chronic lymphocytic leukemia (CLL) is a cancer of the blood and bone marrow that affects older adults. CLL is the most common type of leukemia in adults. It affects B cell lymphocytes, which originate in the bone marrow, develop in the lymph nodes, and normally fight infection by producing antibodies. In 2021, it is expected that there will be 21,250 new cases of CLL and about 4,320 deaths, which represents an increase in both numbers. Patients with CLL are often diagnosed when they are asymptomatic; therefore, knowing when to initiate treatment may pose a challenge to clinicians. Furthermore, patients with CLL have impaired immune systems and multiple comorbidities, which can complicate management and impact treatment decisions. Fortunately for patients with CLL, several new treatments have recently become available giving clinicians many new options to improve patient outcomes with these new treatments and strategies. New combination regimens have recently become available that have shown the ability to greatly improve outcomes in previously untreated CLL. This activity focuses on these evolving options, outlines how to incorporate quality measures for the diagnosis and management of CLL, and describes how to apply evidence-based data to select appropriate treatment regimens and manage toxicities. With the availability of new treatments, it is critical that medical directors, oncologists, nurses and other healthcare professionals are updated on these emerging combination options, guidelines and strategies for implementing them into the treatment paradigm, which will ultimately improve patient outcomes.

After chronic lymphocytic leukemia has been diagnosed, tests are done to find out how far the cancer has spread in the blood and bone marrow. While generally considered incurable, CLL progresses slowly in most cases. CLL treatment focuses on controlling the disease and its symptoms. Initial CLL treatments vary depending on the exact diagnosis and the progression of the disease. Fortunately, clinicians have recently been equipped with more options, including targeted therapies, which individualize therapy for patients with CLL. Additionally, new combination regimens have recently become available that have shown the ability to greatly improve patient outcomes in previously untreated CLL. These new options have shown improved efficacy and safety in CLL, and healthcare professionals must be educated on these options and the potential risks that come along with any treatment option. As the rate at which clinical options for treatment of CLL expands, medical directors, practicing oncologists, nurses and other healthcare professionals providing care for patients with CLL are struggling to stay abreast of these advances. The Spring Managed Care Forum presentation on recent advances in targeted therapy combinations will address this gap in knowledge by providing attendees with updated treatment strategies, guidelines, and successful evidence-based treatment approaches from recent clinical data. With recently approved combination options, and options undergoing regulatory review soon to be entering the treatment paradigm, it is imperative to educate physicians, nurses and other healthcare professionals on these treatments and strategies for patients who would benefit from targeted therapies, ultimately improving patient outcomes.

Upon completion of this activity, participants will be able to:

  • Examine the clinical and economic burden of chronic lymphocytic leukemia (CLL), including factors that contribute to poor prognosis and increased costs

  • Evaluate recent clinical data regarding mechanistic activity, efficacy, and safety of available therapeutic options, and their combinations for CLL

  • Explore the evolving role of BCL-2 and BTK inhibitor combination regimens in the management of previously untreated CLL

  • Identify the optimal use of available CLL agents in terms of sequencing, combination regimens, and duration of therapy within the first-line, high-risk, and R/R settings

  • Discuss strategies to mitigate and manage predictable toxicities that have been reported with the use of new and emerging combination regimens in CLL

  • Assess the managed care considerations of newer combination regimens by exploring where these regimens fit in the evolving CLL treatment paradigm


Faculty: Farrukh T. Awan, MD
Associate Professor of Internal Medicine
Director of Lymphoid Malignancies Program
Harold C. Simmons Comprehensive Cancer Center
University of Texas Southwestern Medical Center


Dr. Awan serves as a consultant for Genetech, AstraZeneca, Abbie, Pharmacyclics, Gilead Sciences, Kite Pharma, Celgene, Karyopharm, MEI Pharma, Verastem, Incyte, Beigene, Johnson and Johnson, Dava Oncology, BMS, Merck, Janssen, Cardinal Health, and ADCT Therapeutics. He has served on the speaker's bureau for Allergan. His presentation has been peer reviewed for any bias.
  Planning Committee:
Bill Williams, MD has no financial relationships with ineligible companies to disclose.
Jeremy Williams has no financial relationships with ineligible companies to disclose.
Jacqueline Cole, RN, MS, CMCN has no financial relationships with ineligible companies to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the National Association of Managed Care Physicians (NAMCP) and American Association of Managed Care Nurses (AAMCN). The National Association of Managed Care Physicians is accredited by the ACCME to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category 1 credit(s)TM. Each
physician should claim credit commensurate with the extent of their participation in the activity.

The American Association of Managed Care Nurses is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in nursing continuing professional development.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This activity is supported by educational grants from
AbbVie, Adaptive Biotechnologies, AstraZeneca, Beigene, and Pharmacyclics

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue